BlackRock Fund Advisors’s PROVECTUS BIOPHARMACEUTICALS, INC. (DE) PVCT Stock Holding History

BlackRock Fund Advisors’s Portfolio PVCT Stock Details PVCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-40,273	Closed	-$4K	–	4313
2016 Q3	$4K	Buy	40,273 +4,221	+12%	+$921	﹤0.01%	4122
2016 Q2	$13K	Buy	36,052 +2,688	+8%	+$1.02K	﹤0.01%	3959
2016 Q1	$13K	Buy	33,364 +7,760	+30%	+$3.2K	﹤0.01%	3945
2015 Q4	$10K	Buy	+25,604	New	+$12.1K	﹤0.01%	4023

Other funds holding PVCT

CCB

Cutter & Co Brokerage Ballwin, Missouri $423M AUM 15.02% 1-Year Est. Return

HFBOT

Home Federal Bank of Tennessee Knoxville, Tennessee $463M AUM 24.62% 1-Year Est. Return

BlackRock Fund Advisors's PVCT Position: Q4 2016 in Review

BlackRock Fund Advisors sold out of PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) in Q4 2016, closing a stake of 40,273 shares — an estimated $4K sold.

BlackRock Fund Advisors first reported a position in PVCT in Q4 2015 and held it in 4 quarters. The position peaked at $13K in Q2 2016. 8 funds tracked by Wall St. Rank hold PVCT as of Q4 2016.

BlackRock Fund Advisors reported no remaining PROVECTUS BIOPHARMACEUTICALS, INC. (DE) position as of Q4 2016 after selling out during the quarter.
BlackRock Fund Advisors sold 40,273 PROVECTUS BIOPHARMACEUTICALS, INC. (DE) shares in Q4 2016, an estimated $4K.
BlackRock Fund Advisors first reported a position in PROVECTUS BIOPHARMACEUTICALS, INC. (DE) in Q4 2015 and held it in 4 quarters.
BlackRock Fund Advisors's PROVECTUS BIOPHARMACEUTICALS, INC. (DE) position peaked at $13K in Q2 2016.
8 funds tracked by Wall St. Rank held PROVECTUS BIOPHARMACEUTICALS, INC. (DE) as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.